DB:F2KA

Stock Analysis Report

Executive Summary

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases.


Snowflake Analysis

Adequate balance sheet with moderate growth potential.

Share Price & News

How has DiaMedica Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: F2KA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

n/a

F2KA

-8.1%

DE Biotechs

0.07%

DE Market


1 Year Return

n/a

F2KA

5.9%

DE Biotechs

14.8%

DE Market

Return vs Industry: Insufficient data to determine how F2KA performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how F2KA performed against the German Market.


Shareholder returns

F2KAIndustryMarket
7 Dayn/a-8.1%0.07%
30 Dayn/a-3.4%1.4%
90 Dayn/a12.2%6.1%
1 Yearn/a6.1%5.9%18.4%14.8%
3 Yearn/a56.9%55.1%17.4%7.0%
5 Yearn/a16.4%13.9%27.9%10.4%

Price Volatility Vs. Market

How volatile is DiaMedica Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is DiaMedica Therapeutics undervalued compared to its fair value and its price relative to the market?

26.43x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate F2KA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate F2KA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: F2KA is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: F2KA is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate F2KA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: F2KA is overvalued based on its PB Ratio (26.4x) compared to the DE Biotechs industry average (3.4x).


Next Steps

Future Growth

How is DiaMedica Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

71.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: F2KA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.5%).

Earnings vs Market: F2KA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: F2KA's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if F2KA's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if F2KA's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if F2KA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has DiaMedica Therapeutics performed over the past 5 years?

21.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: F2KA is currently unprofitable.

Growing Profit Margin: F2KA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: F2KA is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.

Accelerating Growth: Unable to compare F2KA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: F2KA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: F2KA has a negative Return on Equity (-405.42%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is DiaMedica Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: F2KA's short term assets ($6.1M) exceed its short term liabilities ($1.2M).

Long Term Liabilities: F2KA's short term assets ($6.1M) exceed its long term liabilities ($3.7M).


Debt to Equity History and Analysis

Debt Level: F2KA is debt free.

Reducing Debt: F2KA had no debt 5 years ago.


Balance Sheet

Inventory Level: F2KA has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if F2KA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if F2KA has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if F2KA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is DiaMedica Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.5%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate F2KA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate F2KA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if F2KA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if F2KA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of F2KA's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of DiaMedica Therapeutics's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

Rick Pauls (47yo)

9.3yrs

Tenure

US$487,427

Compensation

Mr. Rick Pauls, MBA has been Chief Executive Officer and President of Diamedica Inc. since July 31, 2009. Mr. Pauls was an Executive of GMAC Residential Funding of Canada Ltd. He served as the President of ...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD487.43K) is about average for companies of similar size in the German market ($USD425.50K).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.3yrs

Average Tenure

55yo

Average Age

Experienced Management: F2KA's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

3.1yrs

Average Tenure

57yo

Average Age

Experienced Board: F2KA's board of directors are considered experienced (3.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Management Team

  • Harry Alcorn (62yo)

    Chief Medical Officer

    • Tenure: 0.2yrs
  • Todd Verdoorn (57yo)

    Chief Scientific Officer

    • Tenure: 2.5yrs
    • Compensation: US$337.32k
  • Ed Rady (69yo)

    Chief Commercial Advisor

    • Tenure: 3.1yrs
  • Rick Pauls (47yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$487.43k
  • Mark Williams

    Consultant

    • Tenure: 2yrs
    • Compensation: US$182.28k
  • Dennis Kim (48yo)

    Consulting Chief Medical Officer

    • Tenure: 5.6yrs
    • Compensation: US$11.84k
  • Scott Kellen (53yo)

    CFO & Company Secretary

    • Tenure: 0.6yrs
  • Paul Papi

    Vice President of Business Development

    • Tenure: 1.9yrs

Board Members

  • James Parsons (53yo)

    Director

    • Tenure: 3.1yrs
    • Compensation: US$35.63k
  • Nancy Chang (68yo)

    Member of Strategic Advisory Board

    • Tenure: 1.6yrs
  • R. Giuffre (62yo)

    Director

    • Tenure: 8.3yrs
    • Compensation: US$35.63k
  • Rick Pauls (47yo)

    CEO, President & Director

    • Tenure: 9.3yrs
    • Compensation: US$487.43k
  • Rich Pilnik (61yo)

    Chairman

    • Tenure: 4.3yrs
    • Compensation: US$51.54k
  • Robert Stanton

    Member of Kidney Scientific Advisory Board

    • Tenure: 1.1yrs
  • Philip Bath

    Member of Scientific Advisory Board

    • Paolo Madeddu

      Member of Scientific Advisory Board

      • Jerry Xiao (44yo)

        Director

        • Tenure: 2yrs
        • Compensation: US$35.63k
      • John Volpi

        Member of Scientific Advisory Board

        Company Information

        DiaMedica Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


        Key Information

        • Name: DiaMedica Therapeutics Inc.
        • Ticker: F2KA
        • Exchange: DB
        • Founded: 2000
        • Industry: Biotechnology
        • Sector: Pharmaceuticals & Biotech
        • Market Cap: CA$51.070m
        • Listing Market Cap: CA$34.046m
        • Shares outstanding: 7.86m
        • Website: https://www.diamedica.com

        Number of Employees


        Location

        • DiaMedica Therapeutics Inc.
        • Two Carlson Parkway
        • Suite 260
        • Minneapolis
        • Minnesota
        • 55447
        • United States

        Listings

        TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
        DMATSXV (TSX Venture Exchange)YesCommon SharesCACADMar 2007
        DMCA.DOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 2007
        F2KBST (Boerse-Stuttgart)YesCommon SharesDEEURMar 2007
        F2KADB (Deutsche Boerse AG)YesCommon SharesDEEURMar 2007

        Biography

        DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company’s lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. 


        Company Analysis and Financial Data Status

        All financial data provided by Standard & Poor's Capital IQ.
        DataLast Updated (UTC time)
        Company Analysis2018/11/19 19:32
        End of Day Share Price2018/11/16 00:00
        Earnings2018/06/30
        Annual Earnings2017/12/31


        Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.